and high (Ն20). CD8 + TILs in a subset of patients were also assessed in a quantitative, uncategorized manner, and the functional form of associations with survival was assessed using penalized B-splines.
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We conducted a large-scale assessment of intraepithelial CD8 + TILs in more than 5000 prospectively followed patients with OC. Our goals were to clarify the associations and evaluate the functional form of CD8 + TILs with overall survival in HGSOCs, and to explore association of CD8 + TIL levels with overall survival in patients with other histotypes.
Methods

Study Design and Participants
We assembled a prospective cohort of 7377 women with a primary diagnosis of epithelial ovarian, peritoneal, or fallopian tube cancer, with a final sample size of 5577. Patients were followed from enrollment in an institutional review boardapproved protocol until death from any cause (see eTable 1 in Supplement 1). [24] [25] [26] We requested and received institutional review board/ethics board approval from more than 20 institutions participating in the Ovarian Tumor Tissue Analysis Consortium. None of the studies provided compensation for participants (Supplement 2). Tumor specimens were obtained at initial debulking surgery, formalin fixed, paraffin embedded, and arrayed on tissue microarrays (TMAs). Clinical covariates and vital status underwent standardized quality control measures. We excluded 288 patients owing to loss to follow-up, 11 with missing age at diagnosis, 65 with nonepithelial disease, and 1436 owing to inadequate quality or amount of arrayed tumor tissue. The final sample size of 5577 included 5078 women with tumors of the 5 major invasive histotypes (HGSOC, ENOC, CCOC, MOC, and LGSOC) (see eTable 2 in Supplement 1). The median time from diagnosis to enrollment was zero days (interquartile range, 0-63 days); however, 38% of patients were enrolled more than 1 month after diagnosis. Because some HGSOC may be mistaken as ENOC, 27 we used WT1 and TP53 immunohistochemical staining from 17 studies to reclassify 82 ENOC cases as HGSOC; overall survival of these reclassified patients was consistent with HGSOC (see eFigure 1 in Supplement 1).
Immunohistochemical Analysis and Scoring
For most patients (4669 [84%]), staining was performed at the Mayo Clinic using the Leica Bond RX stainer; however, for patients enrolled at the Study of Epidemiology and Risk Factors and Cancer Heredity (SEA) and Mayo Clinic Ovarian Cancer Study (MAY1) study sites (476 [8%] and 432 [9%], respectively), previously stained slides were used. Immunohistochemical methods are provided in the eMethods in Supplement 1. Scoring was conducted at the University of Calgary; each core was screened for a hotspot of CD8 + TILs using a Nikon eclipse 80i microscope at original magnification ×200. Within each hotspot, 1 high-power field at original magnification ×400 with a 0.55-mm field diameter was evaluated, ensuring comparable area despite different core sizes across studies. Only CD8 + TILs within the epithelial component of the tumor (tumor islets) were considered, and CD8 + cells in the stroma or abutting tumor cells were disregarded (as seen, eg, in eFigure 2 in Supplement 1 classified as negative). A 4-point ordinal score was defined a priori based on CD8 + TIL counts per high-powered field: negative (none), low (1-2 TILs), moderate (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) , and high (≥20 TILs), similar to the validated method of Zhang and colleagues, 4 except that we decreased the low to moderate cutoff from 6 TILs to 3 TILs. We did this to increase ease and consistency of scoring, as a cutoff of 3 or more TILs is routinely used in colorectal carcinoma reporting to assess Lynch syndrome.
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Multiple cores from 156 cases were evaluated blindly by 2 gynecologic pathologists (W.C. and M.K.), and a weighted κ statistic was estimated. Differences in interpretation were discussed at a multiheaded microscope, and the 2 pathologists scored 24% and 76% of the remaining cohort, respectively. The TMAs included an average of 2.4 cores per patient; for cases with more than 1 scored core, the maximum score was used, consistent with the scoring of hotspot regions. 
CD8 + TIL Cut Point Analysis
Because categorical CD8 + TIL cut points may artificially restrict variability in the data and can be somewhat arbitrary, the pathologist (M.K.) rescored all cores from a subset of 2175 patients (1449 with HGSOC), recording CD8 + TIL count as a numeric marker.
Each core was given a value of 0 to 20 or greater, using a threshold of 20 for counts that exceeded that number. As before, the maximum score was used for cases with more than 1 scored core.
Among patients with HGSOC, we compared survival distributions of those with rescored levels to those without using Cox proportional hazards regression. Among HGSOC cases with rescored CD8 + TIL levels, we ran 5 additional sets of Cox regression analyses. We first categorized the levels using our original thresholds (0, 1-2, 3-19, and ≥20 CD8 + TILs) to confirm that our original results using all HGSOC cases did not differ from the subset who were rescored. Second, we categorized the levels using the thresholds of Zhang and colleagues 4 to determine the robustness of our original results to these cut points. Third, we assessed the functional form of the association between CD8 + TIL levels and survival using penalized B-splines. 30 Fourth, we fitted the numerically valued CD8 + TIL levels as a 1 df linear term. Finally, we carried out a formal cut point analysis similar to that described by Budczies and colleagues. 31 Briefly, this approach examines all possible contiguous dichotomizations of TIL levels (ie, 0 vs ≥1, 0-1 vs ≥2, 0-2 vs ≥3) using Cox proportional hazards regression to identify the threshold that best discriminates survivors from nonsurvivors based on evidence of association.
Results
Distribution of CD8 + TILs by Histotype
The final sample included 5577 women; mean age at diagnosis was 58. (Table) . Associations were similar after adjustment for residual disease (see eTable 4 in Supplement 1). Increasing levels of CD8 + TILs were also associated with longer survival time among women with ENOC (P value for trend = .008) (Table; Figure) . This association was also apparent in separate analyses of grade 1 ENOC and grades 2 and 3 ENOC, although these were limited in sample size (see eTable 5inSupplement 1). While there was a statistically significant dose-response similar to HGSOC, it is noteworthy that ENOCs with moderate levels (3-19 per field) showed the greatest improvement in survival time compared with women with ENOC and no detectable CD8 + TILs (HR, 0.50; 95% CI, 0.34-0.74).
A similar association was observed for women with MOC (P = .04) (Table; Figure) , although, as the histotype with the lowest overall levels of CD8 + TILs, only 13 women (4%) had high TIL levels. Kaplan-Meier plots indicate a dose-response relationship, at least for negative to moderate levels ( Figure) . In contrast, CCOCs and LGSOCs showed no apparent association between CD8 + TILs and survival time ( improved survival in a dose-response manner in both surgical outcome groups, indicating that immune response improves prognosis regardless of the remaining residual disease after surgery (see eTable 7 in Supplement 1). Our study included 133 BRCA1 and 66 BRCA2 mutation carriers and 844 tested noncarriers. The extent of CD8 + TILs differed by mutation status (P = .02), as 29% of BRCA1 mutation carriers had high TIL counts, yet only 18% of noncarriers and 15% of BRCA2 mutation carriers did (see eFigure 3 in Supplement 1). The survival benefit associated with CD8 + TILs was also found to differ by mutation status (P value for interaction = .006). Increased CD8 + TILs were associated with favorable survival among cases without mutations (P =5.1×10 −7
) and among cases with a BRCA1 mutation (P = .003) (see eTable 7 in Supplement 1). Among BRCA2 mutation carriers, there was no evidence of association between CD8 + TILs and survival (P = .62). ). In stratified analyses CD8 + TIL level was consistently prognostic in stage and age subgroups (see eTable 5 in Supplement 1). We also observed that patients born more recently showed higher levels (n = 2734, P = .001); we also adjusted all analyses for year of birth, and results were similar. CD8 + TIL level was not associated with year of diagnosis (P = .71), selfreported racial group (P = .74), or pretreatment or posttreatment level of protein CA 125 (P = .42 and .89, respectively).
Analysis of CD8 + TIL Cut Points in HGSOC
Of the 3196 HGSOC cases, 1449 (45%) were rescored using a numeric count. There were no differences in survival between women who were rescored and those who were not (P = . (0, 1-5, 6-19, ≥20 CD8 + TILs) (P <10 −5 for each). As before, associations were slightly attenuated but remained significant after adjustment for extent of residual disease and postsurgical treatment (P <10 −4 for each).
Assessment of the functional form of the association between numeric CD8 + TIL levels and survival using penalized B-splines, after adjustment for age and stage, is shown in eFigure 5 in Supplement 1. We observed a strong negative association with survival, indicating that increasing CD8 + TIL levels are progressively protective across this spectrum of values. The results of fitting CD8 + TIL levels as a 1 df linear term are also shown in eFigure 5 in Supplement 1 and track very closely to those using penalized B-splines, indicating that the association between CD8 + TIL levels and survival in women with HGSOC is virtually log-linear in nature.
Results of a formal cut point analysis examining all possible sets of contiguous dichotomizations of TIL levels can be found in eTable 9 in Supplement 1. The best discrimination of survivors from nonsurvivors occurred when comparing those with 0 to 13 TILs with those with 14 or more (HR, 0.75; 95% CI, 0.65-0.86; P =1.5×10 −5 ). However, each of the 19 dichotomizations yielded highly significant results (P values for all comparisons, ≤1.1 × 10 −3 ), with HRs consistently ranging from 0.75 to 0.83, again indicating that greater TIL levels are protective across the entire spectrum of values examined.
Discussion
To our knowledge, our study is the largest report on intraepithelial CD8 + TILs in OC to date and shows a robust dose-dependent increase in survival for increasing TIL levels in women with HGSOC. Analyses on a subset of individuals using numeric TIL counts confirmed a progressively protective, nearly log-linear survival effect as CD8 + TILs counts increased from 0 to 20 or more per high- 
Limitations
Given its robust prognostic ability, relative ease of testing, and low interobserver variability (percent agreement = 81.8%, Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. 
Immunohistochemistry
Staining at the Mayo Clinic (84% of patients) used the Leica Bond RX stainer (Leica, Buffalo, IL). Dewaxing using Bond Dewax (Leica, Buffalo, IL) and antigens retrieved for 10 minutes using Epitope Retrieval 2 (Leica, Buffalo, IL). The primary antibody (Clone 144B, Dako, Carpinteria, CA) was diluted in Bond Antibody Diluent (Leica, Buffalo, IL) at 1:200 and slides incubated for 15 minutes at room temperature. The detection system was Polymer Refine Detection System (Leica, Buffalo, IL) with visualization using DAB. Slides were counterstained using Schmidt hematoxylin. For two studies (SEA, MAY1), we used previously stained slides, given marker robustness and good visual agreement on restained cases. SEA retrieval used citrate-based unmasking solution and a Dako Autostainer at the University of Cambridge, while MAY1 used EDTA (Chem Lab) and monoclonal CD8 antibody (Dako; M7103) diluted at 1:100 followed by EnVision™ + Dual Link detection system (Dako K4061) at the Mayo Clinic.
Analysis
Intra-tumoral heterogeneity of CD8 values across the multiple cores measured within an individual was examined using intraclass correlation coefficients (ICCs). Specifically, we used the ICC(3,1) method of Shrout and Fleiss (Psychol Bull. 1979;86(2):420-428), assuming a fixed core effect and accounting for the fact that each core was read by the same two pathologists. Overall survival was defined as time from diagnosis to death from any cause, right-censoring at 10 years and accounting for left truncation due to any delayed patient enrollment. For primary associations, we also examined associations using unordered, three degree-of-freedom tests. Progression-free survival analyses considered time from diagnosis to disease progression as provided by each study (eTable 1). Proportional hazards assumptions were formally tested (and not violated), all tests were two-sided and based on a nominal p=0.05 level of significance uncorrected for multiple testing, and all analyses used SAS and R software. Conservatively considering 20 primary tests of hypothesis regarding associations of CD8 + TILs with overall survival (five major invasive histotypes, five subsets of HGSOCs, and 10 other histopathological groupings), one could alternatively utilize p=0.0025 as a statistical significance threshold. 44.3% 0.52 (0.34-0.78) HGSOC, high-grade serous ovarian cancer; adjusted for study, age (continuous), and stage (I/II, III/IV, unknown); mutation status reflects results of germline testing; standard treatment includes 295 patients receiving ≥ four cycles of intra-venous carboplatin AUC 5 or 6 and paclitaxel 135 mg/m² or 175 mg/m² every three weeks and 206 patients receiving ≥ four cycles of intra-venous carboplatin and paclitaxel every three weeks with dose presumed to be carboplatin AUC 5 or 6 and paclitaxel 135 mg/m² or 175 mg/m²; TIL levels based on counts of CD8 + TIL per highpowered field: negative, none; low, 1-2; moderate, 3-19; high, 20+; HR, hazard ratio, CI, confidence interval; P value trend, from a one degree-of-freedom trend test; P value 3 d.f., from an unordered three degree-of-freedom test. As some high-grade serous ovarian carcinomas (HGSOC) may be mistakenly classified as endometrioid ovarian carcinomas during initial pathologic review, we utilized WT1 and p53 immunohistochemical staining information available from 17 studies. Eighty-two endometrioid cases that were positive for WT1 and showed abnormal p53 staining were re-classified as HGSOC. Compared to endometrioid cases that weren't reclassified (solid line), overall survival of cases reclassified as HGSOC was poorer and was consistent with HGSOC. Negative, no CD8 + TILs; low, 1-2 CD8 + TILs; moderate, 3-19 CD8 + TILs; high, 20+ CD8 + TILs per high-powered field.
Numbers of patients are shown within percentages.
eFigure 4.
Negative, no CD8 + TILs; low, 1-2 CD8 + TILs; moderate, 3-19 CD8 + TILs; high, 20+ CD8 + TILs per high-powered field.
The numbers just above the x-axis represent the number of women at risk in two year time intervals. Number at risk on date of diagnosis may be smaller than number at risk later due to left truncation of follow-up resulting from delayed study enrollment.
eFigure 5.
HGSOC, high-grade serous ovarian cancer; hazard ratios (solid red line) and 95% confidence bands (dotted red lines) estimated using penalized B-splines in a Cox proportional hazards regression analysis adjusting for age at diagnosis and tumor stage. Solid black line is hazard ratio modeling CD8 + TIL levels as a one degree-of-freedom linear term in an ageand tumor-stage adjusted Cox regression model.
